CAMBRIDGE, MA, ElevateBio has raised $525 million in a Series C financing led by Matrix Capital Management.
ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, has raised $525 million in a Series C financing.
Matrix Capital Management led the Series C financing alongside additional new investors SoftBank Vision Fund 2 and Fidelity Management and Research Company, who joined ElevateBio's existing investors: MPM Capital, F2 Ventures, Redmile Group, EcoR1 Capital, Samsara BioCapital, The Invus Group, Emerson Collective, Surveyor Capital (A Citadel company), EDBI, Vertex Ventures, iTochu, and a large insurance company.
ElevateBio has created a new disruptive business model addressing the most pressing challenges in the field of cell and gene therapy. With an unprecedented suite of next generation-enabling technologies; including gene editing, induced pluripotent stem cells, and protein, viral, and cellular engineering; the company is changing the way the field advances cell and gene therapies.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about